About Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The companyâ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Get Immix Biopharma, Inc. (IMMX) Logo via API
Integrate this logo into your application with a single API call
Why Use Our Stock Logo API?
Fast Delivery
<100ms response time via global CDN
Enterprise-Ready
99.99% uptime SLA with GDPR compliance
Multiple Formats
SVG, PNG, WebP - scalable to any size
400k+ Logos
Stocks, ETFs, Crypto, Banks, and more
Where to Use Stock Logos
Trading Platforms
Real-time stock displays with instant logo loading
Portfolio Apps
Visualize holdings with recognizable brand logos
Financial Dashboards
Enhance market data with company branding
News & Research
Illustrate articles with accurate company logos
Frequently Asked Questions
The Immix Biopharma, Inc. (IMMX) logo is a trademark of its respective owner. logostream is not affiliated with Immix Biopharma, Inc. (IMMX) and provides this logo for identification purposes only. Logo usage is subject to the trademark holder's brand guidelines -- see our Terms of Service for the attribution requirements that apply to the Logo API.
Need Stock Logos for Your Application?
Access 380,000+ company logos via our simple REST API. Perfect for trading platforms, portfolio apps, and financial dashboards.